rs386833684
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000481.4(AMT):c.471+2T>C variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000958 in 1,461,876 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000481.4 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AMT | NM_000481.4 | c.471+2T>C | splice_donor_variant, intron_variant | ENST00000273588.9 | NP_000472.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AMT | ENST00000273588.9 | c.471+2T>C | splice_donor_variant, intron_variant | 1 | NM_000481.4 | ENSP00000273588.3 | ||||
ENSG00000283189 | ENST00000636166.1 | c.708+2T>C | splice_donor_variant, intron_variant | 5 | ENSP00000490106.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251476Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135920
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1461876Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 727238
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Glycine encephalopathy Pathogenic:7
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 07, 2022 | Variant summary: AMT c.471+2T>C is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4e-06 in 251476 control chromosomes (gnomAD). c.471+2T>C has been reported in the literature in multiple compound heterozygous individuals affected with Glycine Encephalopathy (aka. Non-Ketotic Hyperglycinemia) (Kure_2006, Swanson_2015, Coughlin_2017). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 , and all of them classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Jan 10, 2018 | - - |
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 28, 2023 | ClinVar contains an entry for this variant (Variation ID: 56233). This sequence change affects a donor splice site in intron 4 of the AMT gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in AMT are known to be pathogenic (PMID: 16450403). This variant is present in population databases (rs386833684, gnomAD 0.003%). Disruption of this splice site has been observed in individuals with nonketotic hyperglycinemia (PMID: 16450403). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 02, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 26, 2020 | The AMT c.471+2T>C variant occurs in a canonical splice site (donor) and is therefore predicted to disrupt or distort the normal gene product. The variant has been reported in a compound heterozygous state in at least two unrelated families affected with the neonatal form of glycine encephalopathy (also known as nonketotic hyperglycinemia; NKH). The c.471+2T>C variant was found in trans with a missense variant in one family and with a frameshift variant in the second family (Kure et al. 2006). The c.471+2T>C variant was also identified in five individuals from a cohort of 578 families suspected to have classic NKH (Coughlin et al. 2016). Control data are unavailable for this variant which is found at a frequency of 0.000029 in the Latino population of the Genome Aggregation Database. This frequency is based on one allele in a region of good sequence coverage, so the variant is presumed to be rare. Based on the potential impact of slice donor variants, the variant's rarity and application of the ACMG criteria, the c.471+2T>C variant is classified as pathogenic for glycine encephalopathy. - |
Glycine encephalopathy 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 08, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at